1.52
+0.1(+7.04%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.43 |
| Day High | 1.59 |
| Day Low | 1.36 |
| 52-Week High | 42.4 |
| 52-Week Low | 1.14 |
| Volume | 446,918 |
| Average Volume | 966,262 |
| Market Cap | 4.23M |
| PE | -0.24 |
| EPS | -6.46 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 4.89 |
| Change | 0.1 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $14.99 as of July 03, 2025 at a share price of $1.52. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $438.04 as of July 03, 2025 at a share price of $1.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
GlobeNewswire Inc.
Jun 30, 2025 12:30 PM GMT
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, suppo
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP p
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
GlobeNewswire Inc.
Jun 05, 2025 12:45 PM GMT
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build l